CRIS Current Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
ItalianoPERRONE, GIULIA
Dettaglio
PERRONE, GIULIA
DIPARTIMENTO DI EMATOLOGIA E SCIENZE ONCOLOGICHE "L. e A. SERAGNOLI"
Pubblicazioni
Risultati 1 - 20 di 23 (tempo di esecuzione: 0.001 secondi).
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File | |
|---|---|---|---|---|---|---|---|
| 1 | A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. | Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini... D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M. | 2007 | HAEMATOLOGICA | 1.01 Articolo in rivista | - | |
| 2 | Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. | ARPINATI M; CHIRUMBOLO G; URBINI B; BONIFAZI F; BANDINI G; SAUNTHARARAJAH Y; ZAGNOLI A; STANZANI ...M; FALCIONI S; PERRONE G; TURA S; BACCARANI M.; RONDELLI D. | 2004 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 1.01 Articolo in rivista | - | |
| 3 | Ascorbic acid inhibits antitumor activity of bortezomib in vivo | Perrone G; Hideshima T; Ikeda H; Okawa Y; Calabrese E; Gorgun G; Santo L; Cirstea D; Raje N; Chau...han D; Baccarani M; Cavo M; Anderson KC. | 2009 | LEUKEMIA | 1.01 Articolo in rivista | - | |
| 4 | Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes | Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Briol...i;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo | 2014 | ANNALS OF HEMATOLOGY | 1.01 Articolo in rivista | - | |
| 5 | Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. | Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perr...one G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A. | 2012 | BLOOD | 1.01 Articolo in rivista | - | |
| 6 | Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. | Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M. | 2006 | ANNALS OF HEMATOLOGY | 1.01 Articolo in rivista | - | |
| 7 | Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. | Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccol...ini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M. | 2008 | EUROPEAN JOURNAL OF HAEMATOLOGY | 1.01 Articolo in rivista | - | |
| 8 | First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. | Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; ...Tura S; Baccarani M; Cavo M. | 2006 | EUROPEAN JOURNAL OF HAEMATOLOGY | 1.01 Articolo in rivista | - | |
| 9 | Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 | Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli..., A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M. | 2012 | CANCER RESEARCH | 4.02 Riassunto (Abstract) | - | |
| 10 | HIF 1 Alpha: A Suitable Target for Multiple Myeloma | PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI ...P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M | 2011 | BLOOD | 4.02 Riassunto (Abstract) | - | |
| 11 | HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment | Enrica Borsi;Giulia Perrone;Carolina Terragna;Marina Martello;Elena Zamagni;Paola Tacchetti;Lucia... Pantani;Annamaria Brioli;Angela Flores Dico;Beatrice Anna Zannetti;Serena Rocchi;Michele Cavo | 2014 | EXPERIMENTAL CELL RESEARCH | 1.01 Articolo in rivista | - | |
| 12 | High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 | Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Cri...ppa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M. | 2012 | HAEMATOLOGICA | 4.02 Riassunto (Abstract) | - | |
| 13 | High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 | TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNET...TI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M | 2011 | BLOOD | 4.02 Riassunto (Abstract) | - | |
| 14 | Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. | Borsi E;Perrone G;Terragna C;Martello M;Dico AF;Solaini G;Baracca A;Sgarbi G;Pasquinelli G;Valent...e S;Zamagni E;Tacchetti P;Martinelli G;Cavo M | 2014 | ONCOTARGET | 1.01 Articolo in rivista | - | |
| 15 | Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. | Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Bacca...rani M;Cavo M | 2012 | BONE MARROW TRANSPLANTATION | 1.01 Articolo in rivista | - | |
| 16 | Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. | Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna ...C; Baccarani M; Cavo M. | 2012 | ANNALS OF HEMATOLOGY | 1.01 Articolo in rivista | - | |
| 17 | Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. | Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'ArcoA; Ronconi S; Cellini... C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S;Baccarani M; Cavo M. | 2006 | BLOOD | 1.01 Articolo in rivista | - | |
| 18 | Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. | Cavo M; Terragna C; Renzulli M; Zamagni E; Tosi P; Testoni N; Nicci C; Cangini D; Tacchetti P; Gr...afone T; Cellini C; Ceccolini M; Perrone G; Martinelli G; Baccarani M; Guardigni L. | 2006 | JOURNAL OF CLINICAL ONCOLOGY | 1.01 Articolo in rivista | - | |
| 19 | Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) | Terragna, C.; Renzulli, M.; Remondini, D.; Tagliafico, E.; Roncaglia, E.; Tosi, P.; Zamagni, E.; ...Tacchetti, P.; Perrone, G.; Ceccolini, M.; Brioli, Am.; Martinelli, G.; Baccarani, M.; Cavo, M. | 2007 | 4.02 Riassunto (Abstract) | - | ||
| 20 | Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. | Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda... A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M. | 2009 | JOURNAL OF CLINICAL ONCOLOGY | 1.01 Articolo in rivista | - |
Copyright © 2021